Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Among authors: risebrough na. Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17. Adv Ther. 2022. PMID: 35849317 Free PMC article. Review.
Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.
Exuzides A, Colby C, Briggs AH, Lomas DA, Rutten-van Mölken MPMH, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S. Exuzides A, et al. Among authors: risebrough na. Med Decis Making. 2017 May;37(4):453-468. doi: 10.1177/0272989X15610781. Epub 2015 Oct 8. Med Decis Making. 2017. PMID: 26449490
Validating A Model To Predict Disease Progression Outcomes In Patients With COPD.
Risebrough NA, Briggs A, Baker TM, Exuzides A, Colby C, Rutten van-Molken M, Gonzalez McQuire S, Lomas D, Muellerova H, Tal-Singer R, Ismaila A. Risebrough NA, et al. Value Health. 2014 Nov;17(7):A560-1. doi: 10.1016/j.jval.2014.08.1852. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201846 Free article. No abstract available.
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.
Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA. Briggs AH, et al. Among authors: risebrough na. Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17. Med Decis Making. 2017. PMID: 27317436 Clinical Trial.
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA. Driessen MT, et al. Among authors: risebrough na. Respir Res. 2018 Nov 20;19(1):224. doi: 10.1186/s12931-018-0916-7. Respir Res. 2018. PMID: 30458866 Free PMC article. Clinical Trial.
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.
Paly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, Ismaila AS. Paly VF, et al. Int J Chron Obstruct Pulmon Dis. 2019 May 3;14:939-951. doi: 10.2147/COPD.S188898. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31190781 Free PMC article. Clinical Trial.
33 results